- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
NCCN, Pfizer Grants Section to Collaborate on Biosimilars Initiative
Applicants should show how they would measure biosimilars use and safety in both academic and community practice settings.
The National Comprehensive Cancer Network (NCCN) has announced a collaboration with Pfizer Global Medical Grants, which will provide funding to promote the use of biosimilars in oncology.
NCCN and Pfizer released a request for proposals (RFP) for organizations in the United States to submit letters of intent, “describing concepts that develop and validate enduring approaches to improve the safe, effective and efficient adoption of biosimilars in oncology,” according to a statement released by NCCN. The full proposal is available online at NCCN’s Oncology Research Program site.
The proposals should include the following elements:
- Letters must state how the organizations would measure (1) increases in biosimilar use or (2) efforts to improve “safety, value, and efficiency.”
- Groups must state how they would make measurements in both academic settings and in community oncology practices.
- Factors to be considered are “sustainability and broad applicability of the approach,” and the proposal’s ability “to add value to cancer care delivery.”
Letters of intent are due at 11:59 PM ET on September 9, 2020. Questions should be sent to Nicole Kamienski, kamienski@nccn.org, with the subject line, “2020 Biosimilars Project.”
The NCCN site directs potential applicants to guidance documents from Pfizer on the submission process.
